PharmaTutor
7 June 2016

Applications are Invited for Posts of Pharmacist at NHM

The National Health Mission (NHM) encompassing two Sub-Missions, National Rural Health Mission (NRHM) and National Urban Health Mission (NUHM). It is both flexible and dynamic and is intended to guide States1 towards ensuring the achievement of universal access to health care through strengthening of health systems, institutions and capabilities.

Post: Pharmacist-02 post

7 June 2016
A Review on chemistry and Pharmacological activity of Cinnarizine and Dimenhydrinate combine dosage form

{ DOWNLOAD AS PDF }

ABOUT AUTHORS
Suleman S. khoja, Parthkumar H. Chauhan, Maulik N. Patel, Harsha D. Jani
Department of Quality Assurance,
Shivam Pharmaceutical Studies and Research Centre, Anand, Gujarat.
premukhoja@gmail.com

ABSTRACT
Cinnarizine and Dimenhydrinate combination are active contain and approved by CDSCO The two substances belong to different groups of medicines. Cinnarizine  is a part of a group called calcium antagonists.  Dimenhydrinate belongs to a group called antihistamines Also used in Treatment of vertigo symptoms of various origins. exhibits  anti-emetic and antivertiginous  effects through  influencing the chemoreceptor trigger zone in  the  region of the  4th  ventricle.  Dimenhydrinate thus  acts  predominantly on the central vestibular system.  Due to  its calcium  antagonistic properties, cinnarizine acts  mainly  as a vestibular sedative  through inhibition  of  the calcium  influx  into  the vestibular  sensory cells. Cinnarizine thus acts predominantly on the peripheral vestibular system. Both  cinnarizine and  dimenhydrinate  are  known  to  be effective in  the treatment  of  vertigo.  The combination product is more effective than the individual compounds in the population studied.  The product has not been evaluated in motion sickness. Maximum plasma  concentrations  (Cmax)  of  cinnarizine  and diphenhydramine are reached in  humans  within  2  - 4 hours. metabolised  in  the liver. Cinnarizine is  mainly eliminated  via the  faeces (40-60%) and to a lower extent also in  urine, mainly in the form  of  metabolites conjugated  with  glucuronic acid.  The major route  of  elimination  of diphenhydramine is in  the urine

Mylan N.V. announced the U.S. launch of Clindamycin Palmitate Hydrochloride for Oral Solution USP, 75 mg/5 mL, which is a generic version of Pharmacia and Upjohn's Cleocin® Solution. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of serious infections caused by susceptible anaerobic bacteria and susceptible strains of streptococci, pneumococci and staphylococci when less toxic alternatives are inappropriate.

Mylan N.V. and Biocon Ltd. announced the presentation of data from the HERITAGE study at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 3-7. The study confirmed the efficacy, safety and immunogenicity of MYL-1401O, the proposed biosimilar trastuzumab co-developed by Biocon and Mylan, in comparison to branded trastuzumab.

Regeneron Pharmaceuticals, Inc. and Sanofi announced that a one-year phase 3 study, known as LIBERTY AD CHRONOS, evaluating investigational dupilumab met its primary and key secondary endpoints. In the study, dupilumab with topical corticosteroids (TCS) was compared to TCS alone in moderate-to-severe atopic dermatitis (AD) adult patients. Patients in the study were inadequately controlled by topical corticosteroids (TCS) with or without topical calcineurin inhibitors (TCI). Dupilumab with TCS significantly improved measures of overall disease severity at 16 and 52 weeks, when compared to placebo with TCS.

Roche announced that the European Commission (EC) has approved the subcutaneous (SC) formulation of MabThera® (rituximab) for people with previously untreated and relapsed/refractory chronic lymphocytic leukaemia (CLL). The approved dose for CLL is 1600mg. Following the approval of MabThera SC (1400 mg) for common forms of non-Hodgkin lymphoma in March 2014, this is the second European approval for the formulation.

Mylan N.V.  announced the U.S. launch of Azacitidine for Injection, 100 mg/vial, which is a generic version of Celgene's Vidaza® Injection, 100 mg/vial. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product.

Mylan NV, a global pharmaceutical company, announced the US launch of Propafenone hydrochloride extended-release capsules USP, 225 mg, 325 mg, 425 mg, a generic version of GlaxoSmithKline's Rythmol SR.

Supernus Pharmaceuticals, Inc., announced the issuance of a sixth patent (number 9,351,975) by the United States Patent and Trademark Office (USPTO) covering Oxtellar XR, its novel once-daily extended-release oxcarbazepine product. The patent provides protection for the product with expiration that is no earlier than 2027.

[adsense:336x280:8701650588]

Zydus Cadila, a research-driven, global healthcare provider,  announced that USFDA has approved the company’s plan to initiate a Phase 2 clinical trial of Saroglitazar in patients with Non-Alcoholic Steatohepatitis (NASH) of the liver. This randomized, double-blind Phase 2 trial will evaluate Saroglitazar 1 mg, 2mg and 4 mg Vs. Placebo.